Cellulite is not simply fat. The treatment studied for it does not work at the surface: the radiofrequency is delivered into the subcutaneous layer, under the skin, rather than into the dermis. That is a real difference from the facial protocol most people mean by RF microneedling, which works at dermal depth to remodel collagen.
If you take one thing from this page: the depth is the point. A cellulite treatment and a facial tightening treatment can run on the same machine and still be different treatments.
Alexiades, Munavalli, Goldberg and Berube (2018) ran a prospective multicentre trial across four centres.
93% met that success definition at 6 months. Mean reported pain was 3.74 out of 10. No adverse events were reported. Three quarters of participants said they were satisfied at 6 months.
Blinded grading and a single-session protocol both count in its favour. It is a better-designed study than most in this field.
A later study by Alexiades and Munavalli (2021) treated 31 women across 62 areas — upper arms, above the knee and the bra line — with a single treatment each.
Transient erythema in 69%, swelling in 46% and mild bruising in 32%, all resolving within 5 days.
Results were not uniform by area. Improvement was reported at every timepoint for the arms and bra line, but the area above the knee responded much less consistently.
Being fair to the evidence means being clear about its limits.
None of that makes the 93% figure wrong. It means the finding rests on a single line of evidence.
One device in this class is cleared for cellulite, and it is not Morpheus8. The Profound System (K161043, cleared 15 August 2016) carries the wording "the 75º SubQ handpiece and cartridge are used to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III as supported by long-term clinical data (6 months)". That is the clearance the 93% six-month trial above was generated for — the same subcutaneous protocol, the same investigators. Every other fractional RF microneedling clearance, Morpheus8's included, uses generic electrosurgical wording: electrocoagulation and hemostasis, and since 2023 coagulation or contraction of soft tissue. So treating cellulite with Morpheus8 or with most devices in this class is off-label, which is legal and routine — and note that even a clearance would not be proof of benefit, since 510(k) clearance means substantial equivalence to an earlier device, not that a benefit was demonstrated.
Worth knowing: within the same manufacturer's range, a different applicator type — radiofrequency combined with massage — does carry an on-label claim for "temporary reduction in the appearance of cellulite". That claim belongs to those applicators, not to the microneedling ones.
Radiofrequency microneedling is a device class, not a product. It includes Morpheus8, Potenza, Secret RF, Vivace, Genius, Sylfirm X, Profound and others.
Almost none of the published research used Morpheus8. The cellulite trials above ran on temperature-controlled subcutaneous microneedle RF systems, and the wider literature comes mostly from Lutronic, Jeisys, Pollogen and Lumenis devices.
If you are researching a specific brand, the brand page is the place for brand-specific detail — including the single Morpheus8-specific cellulite case series, whose sample size was not reported in the published record. This page is about what the class as a whole has been shown to do.